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ProliferationZBP-89 can enhance tumor cells to death stimuli. However, the molecular mechanism leading to the
inhibitory effect of ZBP-89 is unknown. In this study, 4 liver cell lines were used to screen for the target of ZBP-
89 on cell death pathway. The identiﬁed Bak was further analyzed for its role in ZBP-89-mediated apoptosis.
The result showed that ZBP-89 signiﬁcantly and time-dependently induced apoptosis. It signiﬁcantly
upregulated the level of pro-apoptotic Bak. ZBP-89 targeted a region between -457 and -407 of human Bak
promoter to stimulate Bak expression based on the ﬁndings of Bak promoter luciferase report gene assay and
electrophoretic mobility shift assay. ZBP-89-induced Bak increase and ZBP-89-mediated apoptosis were
markedly suppressed by Bak siRNA, conﬁrming that Bak was speciﬁcally targeted by ZBP-89 to facilitate
apoptosis. In conclusion, this study demonstrated that ZBP-89 signiﬁcantly induced apoptosis of HCC cells via
promoting Bak level.852 26450605.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Despite a great effort has been made to generate new treatments
for hepatocellular carcinoma (HCC) for decades, surgical resection of
tumor is still the most effective treatment for HCC. However, a
signiﬁcant number of patients with HCC are unresectable at the time
of diagnosis. For these patients, antitumor drugs, especially chemo-
therapeutic agents, will be used to control the tumor growth.
Moreover, HCC patients after surgical resection of tumor usually
need to undergo chemotherapy to kill tumor cells that may not be
completely removed by surgery. It is known that HCC often resists to
chemotherapy. Therefore, there is a need to develop a better
therapeutic regimen for HCC. Our previous study has suggested that
ZBP-89 (also known as ZNF-148, BFCOL1 and BERF-1) might stabilize
p53 in HCC cells and can thus sensitize tumor cells to cell death
stimulation [1]. Our recent experiments have further shown that ZBP-
89 facilitates HCC cell death induced by chemotherapeutic agents
such as 5-ﬂuorouracil (5-FU) [2].
ZBP-89 is a Kruppel-type, zinc ﬁnger transcription factor that binds
to GC-rich elements and activates or represses known target genes.
ZBP-89 has been shown to regulate expression of some molecules
such as p21Waf1 and metalloproteinase 3, gastrin, ornithine decar-boxylase and vimentin [3–8]. By regulating these molecules, ZBP-89
might participate in the control of cell proliferation and growth. In
fact, when overexpressed in gastrointestinal cancer cells, ZBP-89
inhibits cellular proliferation and induces apoptosis [9,10]. Moreover,
the overexpression of ZBP-89 increases caspase-3 levels, induces
TUNEL-positive epithelial cells and abrogates adenoma development
in the ApcMin/+ mouse [10], suggesting that ZBP-89 may function as
a pro-apoptotic molecule or a tumor suppressor. ZBP-89 is known to
inﬂuence the cell growth through either p53-dependent or indepen-
dent mechanisms [9–13]. ZBP-89 might also inhibit the growth of
tumors by suppressing angiogenesis [14]. However, the molecular
mechanism responsible for the pro-apoptotic effect of ZBP-89 on
tumor cells is not understood. In the present study, we explored how
ZBP-89 induced apoptosis in HCC cells by studying Bcl-2 family
members. We have identiﬁed the pro-apoptotic molecule Bak as a
target for ZBP-89. ZBP-89 regulated the expression of Bak by directly
binding its promoter. A knockdown of Bak signiﬁcantly suppressed
ZBP-89-induced apoptosis in HCC cells.
2. Materials and methods
2.1. Cell lines and reagents
The human liver Chang cells and three HCC-derived cell lines:
Hep3B, PLC/PRF/5 and SK-Hep-1 were obtained from the American
Type Culture Collection (Rockville, MD) and were cultured with
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supplemented with 10% heat inactivated fetal bovine serum
(HyClone, Logan, UT) and penicillin/streptomycin. The cells were
maintained at 37 °C in a humidiﬁed atmosphere of 5% CO2.
2.2. Adenovirus ZBP-89 (Ad-ZBP-89) infection
Replication-deﬁcient recombinant Ad-ZBP-89 expressing full-length
Flag-tagged human ZBP-89 cDNA was prepared as previous description
[11,12]. A wide range of multiplicity of infection (MOI) from 1 to 1000
was tested for virus infection. In our study, the cytotoxicity became
apparent when MOI was over 100. We therefore chose MOI 100 as a
standard dose for virus infection. Cells infected with Ad5 vector alone
were set up as control for each experiment [11,12].
2.3. Cell viability assay
Cell death reﬂected by cell viability was measured by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay
[2]. Brieﬂy, cells were grown in 96-well plates (1000 cells perwell). After
24 h, cells were treated with different concentrations of Ad-ZBP-89,
while control cells were treated with empty Ad vector. After 10 to 72 h,
the cells were incubated with MTT solution (Sigma, St Louis, MO) for
another 4 h at 37 °C. The medium was then replaced with 200 μl
dimethyl sulfoxide. ReducedMTTwasmeasured spectrophotometrically
in a dual beam microtiter place reader at 560 nm with a reference
wavelength of 670 nm.
2.4. Detection of apoptosis
Cells seeded onto 6-well plates were treated by MOI 100 Ad-ZBP-
89 and incubated for 10, 24, 48 and 72 h. The control cells treated with
empty Ad vector were included in every experiment. After the
indicated time periods, cells were collected and the number of
apoptotic cells was determined by TUNEL assay and quantiﬁed by
ﬂow cytometry. The results were plotted as a percent of the 0 h
control conditions.
2.5. Western blot
Western blots were performed according to the standard methods
published elsewhere [1–4]. Brieﬂy, cells were lysed by incubation on
ice for 15 min in RIPA buffer to isolate total proteins. The protein
extracts (30 μg) were separated by 10–15% SDS (sodium dodecyl
sulphate)-polyacrylamide gel electrophoresis and transferred onto
Hybond ECL nitrocellulose membrane for electoblotting. The primary
antibodies used were anti-ZBP-89 (Abnova Corporation), anti-Bak
(Cell Signalling Technology), anti-Bcl-2, (Santa Cruz Biotechnology)
and anti-cytochrome c (ZYMED Laboratories). The primary reaction
was followed by incubation with HRP-conjugated secondary anti-
bodies and the blots were developed by ECL enhanced chemilumi-
nescence system (Amersham Biosciences, Buckinghamshire, UK) and
exposed to X-Ray ﬁlm. As a control for sample loading, the blot was
stripped and reprobed with anti-actin polyclonal antibody (Santa
Cruz Biotechnology). The density of the protein bands was quantiﬁed
using a GSP-700 scanner and Quantity One Image software (Bio-Rad,
Hercules, CA).
2.6. Luciferase activity assay
Ten different Bak promoter fragments (181–1965pb) were
prepared by the sequential 5′ deletion of the human Bak promoter
(-1965, to -1) (Fig. 3C) [15]. After the initial analysis of these 10 Bak
promoter fragments, ﬁve truncated (about 100 bp each) Bak
fragments were further generated from the Bak promoter region
between -706 and -287 (Fig. 3D). These fragments were cloned intopGL3 (Promega, Madison, WI). The sequence of different Bak
fragments was conﬁrmed by sequencing (ABI PRISMTM, Applied
Biosystems, Foster City, CA). Cells were transfected with the Bak
promoter plasmid, pGL3-basic plasmid or pGL3-control plasmid. After
6 h of transfection, the transfected cells were infected with a MOI of
100 Ad-ZBP-89, then incubated for an additional 24 h. After
incubation, the lysate was isolated. Renilla luciferase assay was then
performed on cell lysates using the Dual-Lucifearse Reporter Assay
System (Promega, Madison, WI) according to the manufacturer's
instructions. Control Renilla luciferase activity was used to determine
transfection efﬁciency. The activation ratio (fold activation) was
determined by dividing the normalized ﬁreﬂy luciferase counts in the
presence and absence of Ad-ZBP-89.
2.7. Electrophoretic mobility shift assay (EMSA)
A standard EMSA was used to further examine whether ZBP-89
protein from the human liver nuclear extracts binds to the Bak
promoter region -457/-407. Cells were plated on a 6-well plate and
transfected with pGL3-Bak promoter for 6 h. Cells were then treated
with MOI100 Ad-ZBP-89 for another 24 h. At the end of the
incubation, the nuclear extract was prepared. Three pairs of Bak
Gel-shift complementary oligonucleotides (50 bp each) were
annealed and biotinylated using biotin 3′ end-labeling kit (Pierce,
Rockford, IL). EMSA was carried out with the Light Shift chemilumi-
nescent EMSA kit (Pierce, Rockford, IL) according to the manufac-
turer's instruction. Brieﬂy, the binding reactions were analyzed by
electrophoresis through a native 6% polyacrylamide gel. After
transferring the binding reactions to the nylon membrane, it was
cross-linked in a transilluminator and passed several chemilumines-
cence steps before being exposed to X-ray ﬁlm to visualize the DNA-
protein complexes.
2.8. RNA interference
For siRNA-mediated knockdown of ZBP-89 and Bak genes, the pre-
designed siRNA targeting the exon 5 of the human ZBP-89
(NM_021964) was used to block of ZBP-89, and the target-speciﬁc
20–25nt siRNA was employed to knockdown the Bak gene in cells.
ZBP-89 siRNA and its negative control were synthesized by Ambion
Silencer Select Pre-designed siRNA (Ambion, Applied Biosystems).
Bak siRNA and its negative control were obtained from Santa Cruz
Biotechnology. Their respective complementary oligonucleotides
were also synthesized, annealed to form double-stranded siRNA and
were used in transfection at a ﬁnal concentration of 50 nM. They were
mixed with 175 μl of OPTI-MEM (Gibco) and incubated for 10 min. A
mixture of 3 μl of lipofectamine 2000 reagent (Invitrogen) and 12 μl of
OPTI-MEM was then added to the above and incubated for 20 min.
Mediumwas removed from adherent HCC cells, theywere then plated
in 800 μl of OPTI-MEM overlaid with 200 μl of the siRNA mixture in a
6-well dish.
2.9. Data analysis
All results are expressed as mean±SD of at least three indepen-
dent experiments. Differences between groups were examined for
statistical signiﬁcance using Student's t-test (paired, two sided) or one
way ANOVA followed by Student's t-test. pb0.05 was used to indicate
a statistically signiﬁcant difference.
3. Results
3.1. Overexpression of ZBP-89 induces liver cell death
To examine the effect of Ad-ZBP-89 on cell death of liver cells,
Hep3B, PLC/PRF/5, SK-Hep-1 and Chang cells were infected with 5
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24, 48 and 72 h after infection to measure cell death which was
reﬂected by the reduced cell viability. As shown in Fig. 1, cell death
induced by Ad-ZBP-89 appeared to be time- and dose-dependent. It
was noted that the concentration of Ad-ZBP-89 at or higher than a
MOI 100 caused apparent cell death. Therefore we choose a MOI 100
as the standard dose for the subsequent experiments. Compared with
Chang cells, cell death induced by Ad-ZBP-89 was greater in the 3 HCC
cells tested.
It was not clear whether cell death induced by Ad-ZBP-89 was
due to apoptosis or another mechanism.We therefore employed two
methods to determine whether apoptosis occurred, the TUNEL assay
and cytochrome (cyto) c release. The TUNEL assay showed that Ad-
ZBP-89 signiﬁcantly induced apoptosis of all cells tested in a time-
dependent manner (Fig. 2A). The SK-Hep-1 cells were the most
sensitive to Ad-ZBP-89 while the Chang cells were the least sensitive
to Ad-ZBP-89. The cyto c release experiments indicated that upon
Ad-ZBP-89 treatment, cyto c was released from the mitochondria
into the cytosol, resulting in an increase in the level of cytosolic cyto
c and a decrease in mitochondrial cyto c (Fig. 2B). The ﬁnding
conﬁrmed the result obtained by TUNEL assay and also suggested
that the apoptosis induced was mediated via a mitochondrial-
related pathway. The results of the TUNEL assay and cyto c release
were in agreement with the cell death detected by the MTT assay.Hep3B Ad-ZBP89 (MOI)
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Fig. 1. Cell death induced by ZBP-89. Cell death, reﬂected by the reduction of cell viability, wa
96 well plates and infected with Ad-ZBP-89 at different concentrations. Cells infected with
incubated for 10, 24, 48 and 72 h until the MTT assay was performed. The viability of th
were reported as the mean ± SD of three separate experiments. The signiﬁcant difference in
with Ad-ZBP-89 at indicated time points (*pb0.05 and **pb0.01).Therefore, we concluded that cell death induced by Ad-ZBP-89 was
mainly due to apoptosis.
3.2. ZBP-89 induces Bak expression in liver cells
To further investigate the mechanism of ZBP-89-induced apopto-
sis, we infected the liver cell lines with a MOI of 100 Ad-ZBP-89. The
cells were collected at different time points between 10 and 72 h after
virus infection. Total protein was extracted and Western blot was
performed to examine the expression of ZBP-89, Bcl-2 and pro-
apoptotic Bcl-2 family members including Bax, Bid and Bak. As shown
in Fig. 3, infection with the Ad-ZBP-89 dramatically increased ZBP-89
levels. Ad-ZBP-89 did not obviously affect Bcl-2 in cell lines tested
(Fig. 3A), suggested that Bcl-2 might not contribute to the apoptosis
induced by Ad-ZBP-89. Among pro-apoptotic Bcl-2 family members,
Ad-ZBP-89 signiﬁcantly up-regulated the level of Bak at 24 or 48 h
after the infection (Fig. 3A and B) but did not obviously affect Mcl-1,
Bax and Bid (data not shown). Similar to changes in the expression of
Bak protein, the expression of Bak mRNA was also increased in cells
infected with Ad-ZBP-89 (data not shown).
To explore the mechanism of Bak gene activation by ZBP-89, SK-
Hep-1 cells were selected for the further investigation using Bak
reporter constructs. Ten different Bak promoter fragments (181–
1965 bp) were prepared by the sequential 5′ deletion of the humanvi
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Fig. 2. Ad-ZBP-89 induced apoptosis in liver cells. Hep3B, PCL/PRF/5, SK-Hep-1 and Chang cells were infected with MOI 100 Ad-ZBP-89 or with empty Ad vector as control. After 10,
24, 48 and 72 h, cells were harvested and analyzed by TUNEL for apoptosis (A). For the cytochrome (cyto) c release experiment, themitochondria (Mito) and cytosolic (CTS) fractions
were isolated and subjected to Western blot analysis to measure the level of cyto c in these two fractions (B). Actin was used as the loading controls. Compared with the control:
*pb0.05 and **pb0.01.
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these 10 Bak promoter fragments, ﬁve shorter (about 100 bp each)
Bak fragmentswere generated from the Bak promoter region between
-706 and -287. We found that ectopic expression of ZBP-89
signiﬁcantly activated the -706 and -288 Bak promoters in SK-Hep-
1 cells (Fig. 3C), suggesting that the protein-DNA binding site of ZBP-
89 at the Bak promoter was within a 419 bp region between -706 and
-288. We further divided this 419 bp fragment into ﬁve ~100 bp
fragments with an ~10 bp overlap between segments. Luciferase
assays were then performed to further identify the potential Bak-ZBP-
89 binding sitewithin the ﬁve shortened Bak promoter fragments. The
result showed that ZBP-89 induced the Bak promoter activity through
DNA elements residing at -527-428 and -437-338 (Fig. 3C). The
ﬁnding suggested that ZBP-89 inducible element resides within a
189 bp fragment between -527 and -338.
In order to test whether the candidate protein ZBP-89 binds to
the putative regulatory elements, we randomly generated three
pairs of gel shift probes from sequences within the 189 bp response
element (Fig. 3D). The results showed a clear shifted complex when
the 50 bp oligonucleotide B probe containing the Bak promoter
sequence from -457 to -408 was incubated with Ad-ZBP-infected
cells. Unlabeled probe competed with labelled probe for the shifted
complex and thus blocked formation of the shifted complex. The
ﬁnding conﬁrmed the speciﬁcity of binding and demonstrated that aprotein:DNA binding/interaction existed between ZBP-89 protein
and the Bak promoter at -457 to -407 region.
3.3. Knockdown of ZBP-89 prevents Bak expression
In order to conﬁrm ZBP-89 induction of Bak promoter, ZBP-89
siRNA was used to block ZBP-89 expression in liver cells. Double
stranded ZBP-89 siRNA was transfected into cells and reduced ZBP-89
protein levels within 24 and 48 h after treatment (Fig. 4). As expected,
suppression of ZBP-89 expression by its siRNA effectively reduced the
Bak expression in PLC/PRF/5 and SK-Hep-1 (Fig. 4). These results
convincingly showed that ZBP-89 was a positive regulator of the Bak
promoter. Compared with no treatment, knockdown of ZBP-89
increased the level of Bcl-2 in HCC cells, especially in SK-Hep-1 and
Hep 3B, but had no effect in Chang cells (Fig. 4).
3.4. Knockdown of ZBP-89 increases cell growth
Having conﬁrmed the apoptotic effect of ZBP-89 by TUNEL and
cyto c release assays and the promoting effect of ZBP-89 on Bak by
ZBP-89 siRNA, we further tested whether the inhibition of ZBP-89
had a positive effect on the growth of liver cells. We therefore
treated the liver cells with ZBP-89 siRNA, then measured the cell
death using the MTT viability assay. The ﬁndings showed that ZBP-
226 A.K.Y. To et al. / Biochimica et Biophysica Acta 1813 (2011) 222–23089 siRNA signiﬁcantly enhanced the growth of liver cells, compared
with the mock control (Fig. 5). The effect of ZBP-89 siRNA was time-
dependent. Among the 4 types of cells tested, it appeared that SK-A
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of Bak and apoptosis
Bak siRNAwas employed to conﬁrmwhether Bak was the target of
ZBP-89. We ﬁrst measured Bak level in HCC cells transfected with Bak
siRNA and the result showed that the level of Bak was inhibited by its
siRNA in liver cells and the level was completely blocked in Hep3B,
PLC/PRF/5 and SK-Hep-1 cells at 48 h after transfection (Fig. 6A). Bak
siRNA blocked Bak expression in Chang cells at 72 h after transfection.Hep3B
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be reduced by knockdown of Bak expression in liver cells. The result
showed that the ZBP-89-mediated apoptosis was signiﬁcantly
reduced by Bak siRNA in Hep3B, PLC/PRF/5 and SK-Hep-1 cells
(Fig. 6C). Among these three types of cells, the reduction of apoptosis
by Bak siRNA was greatest in SK-Hep-1. The apoptosis in Chang cells
was only slightly reduced by Bak siRNA. These ﬁndings were
consistent with the fact that three HCC cell lines were much more
sensitive to ZBP-89/Bak-mediated apoptosis than Chang cells (Figs. 2
and 6B).
4. Discussion
In this study we have provided evidence that ZBP-89 induces
apoptosis of HCC cells by inducing Bak. First, ZBP-89 can signiﬁcantly
enhance the protein level of Bak, which can be blocked or signiﬁcantly
inhibited by either ZBP-89 siRNA or Bak siRNA. Second, ZBP-89-
induced apoptosis is markedly inhibited by Bak siRNA. To the best of
our knowledge, there are no publications addressing the relationship
between Bak and ZBP-89. Bak is a well known cell death initiator in
the apoptotic signaling cascade [16,17]. Upon stimulation, Bak
undergoes some conformational changes, leading to formation of
higher order Bak multimers, mitochondrial membrane permeabiliza-
tion and the release of pro-apoptotic factors such as cytochrome c into
the cytoplasm. Consistent with this known concept, we have observed
a signiﬁcant increase in cytochrome c in the cytoplasm upon ZBP-89
treatment. The role of Bak in the hepatocarcinogensis or HCCtreatment has also been documented. The level of Bak is reduced
[18,19] or even non-detectable in HCC cells [20]. The pro-apoptotic
role of Bak in HCC cells is further supported by several experiments in
which different agents induce apoptosis in HCC cells by stimulating
Bak expression [21–23]. The overexpression of Bak may sensitize HCC
cells to apoptosis induced by the chemotherapeutic agent doxorubicin
[24]. It is well known that therapy resistance is a common clinical
problem in HCC management. Resistance to apoptosis is a principal
mechanism through which HCC cells escape from various cell death
inducers [25]. Therefore, the ﬁnding that ZBP-89 induces apoptosis by
promoting Bak is therapeutically signiﬁcant for HCC management.
ZBP-89 did not obviously affect the level of Bcl-2 in all four cell
lines tested, indicating that Bcl-2 dose not appear to play a role in ZBP-
89-mediated apoptosis of liver cells. Bai et al. previously examined
several anti- and pro-apoptotic molecules regulated by ZBP-89 [13].
Indeed, they found that ZBP-89 siRNA induced Bcl-xL in gastrointes-
tinal cancer cells, indicating that this anti-apoptotic molecule is
regulated by ZBP-89. The ﬁnding suggests that Bcl-xL might be the
preferred anti-apoptotic protein targeted in those cells treated by
ZBP-89. However, whether this is the case in HCC cells remains further
investigation.
By using RT-PCR and Western blot analyses, we showed that all
cells tested (Hep3B, PLC/PRF/5, SK-Hep-1 and Chang) are able to
constitutively express endogenous Bak. The base level of Bak can be
greatly enhanced by ZBP-89 treatment and the increase in Bak is
functional in terms of apoptotic induction in HCC cells. In order to
better understand the role of ZBP-89, a transcriptional factor, in the
229A.K.Y. To et al. / Biochimica et Biophysica Acta 1813 (2011) 222–230induction of Bak, we isolated overlapping Bak promoter fragments.
Once a 189 bp element was identiﬁed using the reporter constructs,
EMSAs were used to narrow the regulatory element to a 50 bpTreatment
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230 A.K.Y. To et al. / Biochimica et Biophysica Acta 1813 (2011) 222–230genome.ad.jp/). Therefore, all these results support that the human
Bak promoter contains the binding site for ZBP-89 and that ZBP-89 is
able to bind the promoter to induce Bak expression.
Therefore, we conclude that ZBP-89 markedly induced Bak
expression by interacting with its promoter. Subsequently, Bak
induction causes apoptosis of HCC cells. We have noted that factors
other than Bak are likely to also contribute to the apoptosis induced by
ZBP-89 because Bak siRNA does not completely prevent the ZBP-89-
mediated apoptosis. Nevertheless, our ﬁnding contributed to under-
standing how ZBP-89 induces apoptosis in HCC, which may provide
some useful information for us to improve the efﬁcacy of anti-HCC
chemotherapy.
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